Johan Lombaard, Francis Ssali, Visal Moolasart, Alfredo Guarino, Raffaele Badolato, Stefania Bernardi, Margarida Tavares, Claudia Fortuny, Linda Aurpibul, Supattra Rungmaitree, Rodica Van Solingen-Ristea, Veerle Van Eygen, Sandy Van Hemelryck, Alberto Russu, Ken Kurosawa, Minaka Shibuya, Simon Vanveggel, Erika Van Landuyt
{"title":"在病毒学抑制的HIV-1感染儿童中，改用口服利匹韦林联合其他抗逆转录病毒治疗的药代动力学、安全性、耐受性和抗病毒活性：来自2期、开放标签、单臂、PICTURE研究的48周结果","authors":"Johan Lombaard, Francis Ssali, Visal Moolasart, Alfredo Guarino, Raffaele Badolato, Stefania Bernardi, Margarida Tavares, Claudia Fortuny, Linda Aurpibul, Supattra Rungmaitree, Rodica Van Solingen-Ristea, Veerle Van Eygen, Sandy Van Hemelryck, Alberto Russu, Ken Kurosawa, Minaka Shibuya, Simon Vanveggel, Erika Van Landuyt","doi":"10.1097/INF.0000000000004943","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>PICTURE (NCT04012931) was a phase 2, open-label, single-arm, multicenter study evaluating pharmacokinetics (PK), safety, tolerability and antiviral activity of oral rilpivirine in combination with other antiretroviral therapy (ART) in children living with HIV-1 with virologic suppression.</p><p><strong>Methods: </strong>Children (≥2 to <12 years, ≥10 kg) living with HIV-1, virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ART were enrolled. Weight-based rilpivirine [25 mg once-daily (qd) for ≥25 kg, 15 mg (6 × 2.5 mg) qd for 20 kg to <25 kg and 12.5 mg (5 × 2.5 mg) qd for 10 to <20 kg in film-coated or investigational dispersible tablet formulations] was administered orally in combination with background ART for 48 weeks. The primary objectives were evaluation of rilpivirine steady-state PK, determination of an appropriate weight-based dose, and safety and tolerability when combined with other ARTs. Results of the primary (week 24) and final (week 48) analyses are presented.</p><p><strong>Results: </strong>Of 40 participants screened, 26 (65%) were enrolled and treated with rilpivirine. All participants completed the week 48 visit and were included in the final analysis. PK parameters were observed to be in the target range for all rilpivirine weight-based doses. Through week 48, 19/26 (73.1%) participants had ≥1 adverse event; all grade 1-2 and none were treatment related. All 26 participants (100%) receiving rilpivirine in combination with ART remained virologically suppressed at both weeks 24 and 48. Adherence to treatment was 98.99%.</p><p><strong>Conclusion: </strong>Rilpivirine in combination with background ART was well-tolerated and maintained virologic suppression from baseline through week 48 in the studied population of children living with HIV-1. Rilpivirine exposure was within the target range for all doses.</p>","PeriodicalId":19858,"journal":{"name":"Pediatric Infectious Disease Journal","volume":" ","pages":"1072-1078"},"PeriodicalIF":2.2000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE Study.\",\"authors\":\"Johan Lombaard, Francis Ssali, Visal Moolasart, Alfredo Guarino, Raffaele Badolato, Stefania Bernardi, Margarida Tavares, Claudia Fortuny, Linda Aurpibul, Supattra Rungmaitree, Rodica Van Solingen-Ristea, Veerle Van Eygen, Sandy Van Hemelryck, Alberto Russu, Ken Kurosawa, Minaka Shibuya, Simon Vanveggel, Erika Van Landuyt\",\"doi\":\"10.1097/INF.0000000000004943\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>PICTURE (NCT04012931) was a phase 2, open-label, single-arm, multicenter study evaluating pharmacokinetics (PK), safety, tolerability and antiviral activity of oral rilpivirine in combination with other antiretroviral therapy (ART) in children living with HIV-1 with virologic suppression.</p><p><strong>Methods: </strong>Children (≥2 to <12 years, ≥10 kg) living with HIV-1, virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ART were enrolled. Weight-based rilpivirine [25 mg once-daily (qd) for ≥25 kg, 15 mg (6 × 2.5 mg) qd for 20 kg to <25 kg and 12.5 mg (5 × 2.5 mg) qd for 10 to <20 kg in film-coated or investigational dispersible tablet formulations] was administered orally in combination with background ART for 48 weeks. The primary objectives were evaluation of rilpivirine steady-state PK, determination of an appropriate weight-based dose, and safety and tolerability when combined with other ARTs. Results of the primary (week 24) and final (week 48) analyses are presented.</p><p><strong>Results: </strong>Of 40 participants screened, 26 (65%) were enrolled and treated with rilpivirine. All participants completed the week 48 visit and were included in the final analysis. PK parameters were observed to be in the target range for all rilpivirine weight-based doses. Through week 48, 19/26 (73.1%) participants had ≥1 adverse event; all grade 1-2 and none were treatment related. All 26 participants (100%) receiving rilpivirine in combination with ART remained virologically suppressed at both weeks 24 and 48. Adherence to treatment was 98.99%.</p><p><strong>Conclusion: </strong>Rilpivirine in combination with background ART was well-tolerated and maintained virologic suppression from baseline through week 48 in the studied population of children living with HIV-1. Rilpivirine exposure was within the target range for all doses.</p>\",\"PeriodicalId\":19858,\"journal\":{\"name\":\"Pediatric Infectious Disease Journal\",\"volume\":\" \",\"pages\":\"1072-1078\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Infectious Disease Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/INF.0000000000004943\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Infectious Disease Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/INF.0000000000004943","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE Study.
Background: PICTURE (NCT04012931) was a phase 2, open-label, single-arm, multicenter study evaluating pharmacokinetics (PK), safety, tolerability and antiviral activity of oral rilpivirine in combination with other antiretroviral therapy (ART) in children living with HIV-1 with virologic suppression.
Methods: Children (≥2 to <12 years, ≥10 kg) living with HIV-1, virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ART were enrolled. Weight-based rilpivirine [25 mg once-daily (qd) for ≥25 kg, 15 mg (6 × 2.5 mg) qd for 20 kg to <25 kg and 12.5 mg (5 × 2.5 mg) qd for 10 to <20 kg in film-coated or investigational dispersible tablet formulations] was administered orally in combination with background ART for 48 weeks. The primary objectives were evaluation of rilpivirine steady-state PK, determination of an appropriate weight-based dose, and safety and tolerability when combined with other ARTs. Results of the primary (week 24) and final (week 48) analyses are presented.
Results: Of 40 participants screened, 26 (65%) were enrolled and treated with rilpivirine. All participants completed the week 48 visit and were included in the final analysis. PK parameters were observed to be in the target range for all rilpivirine weight-based doses. Through week 48, 19/26 (73.1%) participants had ≥1 adverse event; all grade 1-2 and none were treatment related. All 26 participants (100%) receiving rilpivirine in combination with ART remained virologically suppressed at both weeks 24 and 48. Adherence to treatment was 98.99%.
Conclusion: Rilpivirine in combination with background ART was well-tolerated and maintained virologic suppression from baseline through week 48 in the studied population of children living with HIV-1. Rilpivirine exposure was within the target range for all doses.
期刊介绍：
The Pediatric Infectious Disease Journal® (PIDJ) is a complete, up-to-the-minute resource on infectious diseases in children. Through a mix of original studies, informative review articles, and unique case reports, PIDJ delivers the latest insights on combating disease in children — from state-of-the-art diagnostic techniques to the most effective drug therapies and other treatment protocols. It is a resource that can improve patient care and stimulate your personal research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
